Data from multiple sources - Curated by Marshall Pearce - Last updated 04 July 2017

Non-Hodgkin lymphoma

Non-Hodgkin lymphoma (NHL) comprises a heterogenous group of lymphoid tissue tumours, distinguished from Hodgkin’s lymphoma by their absence of Reed-Sternberg cells on ...


Read more on Non-Hodgkin lymphoma

 

Latest news articles

Added 11 hours ago Drug news

EC approves Adcetris for CD30-positive cutaneous T-cell lymphoma.

The European Commission (EC) extended the current conditional marketing authorization of Adcetris (brentuximab vedotin).

Added 5 days ago Drug news

Kymriah first CAR-T therapy available for distinct indications in non-Hodgkin lymphoma and B-cell ALL

FDA priority review and EMA accelerated assessment for Kymriah for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Added 1 month ago Drug news

Revlimid + rituximab combination fails phase III RELEVANCE study for follicular lymphoma.- Celgene.

Celgene Corporation and the Lymphoma Study Association announced that the Lymphoma Academic Research Organisation (LYSARC) reported results from a phase...

Search all news articles for Non-Hodgkin lymphoma
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars in Oncology Knowledge Centre

Biosimilars in Oncology Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

Load more

Guidelines

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Mantle cell lymphoma is a relatively uncommon subtype of lymphoid malignancy and is more often found in males than in females. These updated ESMO guidelines provide treatment recommendations...

Added 3 years ago

ESMO Consensus Conference on Malignant Lymphoma: General Perspectives and Recommendations for Prognostic Tools in Mature B-cell Lymphomas and Chronic Lymphocytic Leukaemia

In order to complement the already available European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with malignant lymphomas, ESMO organised a consensus conference...

Added 1 year ago

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Follicular lymphomas are the second most frequent subtype of nodal lymphoid malignancies in Western Europe. The annual incidence of this disease is rare but has increased during recent decades.

Added 1 year ago

Search all guidelines for Non-Hodgkin lymphoma
 

Journal articles

Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.

Background: B-cell survival is regulated through interactions of B-cell-activating factor and a proliferation-inducing ligand with their receptors transmembrane activator and CAML interactor (TACI) and B-cell maturation antigen...

Added 13 days ago

Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.

Introduction: A combination of granulocyte colony-stimulating factor (G-CSF) and chemotherapy or G-CSF alone are the most common mobilization regimens for autotransplantations.

Added 3 months ago

Plerixafor for stem cell mobilization: the current status.

Purpose of review: Nowadays, plerixafor is approved for patients who fail to mobilize sufficient CD34⁺ cells for an autologous stem cell transplantation. Plerixafor is effective in the majority of these patients...

Added 3 months ago

Search all journal articles for Non-Hodgkin lymphoma
 

Clinical trials

A Randomized Double-blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

This randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma...

Added 7 months ago

ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

The primary objective of the the trial is to establish one of three study arms...

Added 1 year ago

Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial

The primary objective of the the trial is to establish one of three study arms, as future standard based on the comparison of the investigator...

Added 7 months ago

Search all clinical trials for Non-Hodgkin lymphoma
 
Fiona Holland

Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more

What to say and do when someone has cancer

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.

CME

Night sweats - red flag symptoms

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
0
Registration required
1
Subscription fee
0
Search all CME for Non-Hodgkin lymphoma